ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Birmingham, AL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Birmingham, AL, USA:

Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/taxol/pembro, Maintenance Olaparib/pembro

this is a trial evaluating three chemotherapy agents in patients with newly diagnosed ovarian cancer patients that are Stage III or...

Enrolling
Ovarian Cancer
Drug: olaparibp, embro
Drug: Carboplatin

Phase 2

The University of Alabama at Birmingham
The University of Alabama at Birmingham

Birmingham, Alabama, United States

of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...

Active, not recruiting
Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy
Drug: Placebo to match olaparib 300mg
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Birmingham, Alabama, United States and 125 other locations

in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian...

Active, not recruiting
Primary Peritoneal Cancer
Fallopian Tube Cancer
Biological: Pembrolizumab
Drug: Gemcitabine

Phase 3

Mural Oncology

Birmingham, Alabama, United States and 118 other locations

of REGN4018 can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus* The study will ...

Enrolling
Recurrent Primary Peritoneal Cancer
Recurrent Ovarian Cancer
Drug: REGN4018
Drug: Sarilumab

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Birmingham, Alabama, United States and 53 other locations

This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus...

Active, not recruiting
Primary Peritoneal Cancer
Epithelial Ovarian Cancer
Biological: IMNN-001
Drug: Carboplatin

Phase 1, Phase 2

IMUNON
IMUNON

Birmingham, Alabama, United States and 20 other locations

of sovilnesib at different dose levels to establish the Recommended Phase 2 Dose (RP2D) of sovilnesib in subjects with high grade serous ovarian...

Enrolling
Fallopian Tube Cancer
Primary Peritoneal Carcinoma
Drug: Sovilnesib

Phase 1

Volastra Therapeutics

Birmingham, Alabama, United States and 12 other locations

and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary perito...

Active, not recruiting
Peritoneal Neoplasms
Fallopian Tube Cancer
Drug: Docetaxel
Drug: Placebo for olaparib

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Birmingham, Alabama, United States and 226 other locations

This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It wi ...

Enrolling
Ovarian Neoplasms
Gastric Cancer
Drug: pembrolizumab
Drug: PF-08046054

Phase 1

Seagen, a wholly owned subsidiary of Pfizer

Birmingham, Alabama, United States and 43 other locations

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like you...

Enrolling
Other Solid Tumors
Ovarian Neoplasms
Drug: PF-08052666

Phase 1

Seagen, a wholly owned subsidiary of Pfizer

Birmingham, Alabama, United States and 18 other locations

is a type of drug known as a PARP inhibitor. Some types of breast cancer and ovarian cancer share some basic features that...

Active, not recruiting
Somatic Mutation Breast Cancer (BRCA1)
Somatic Mutation Breast Cancer (BRCA2)
Drug: Olaparib

Phase 2

Beth Israel Lahey Health
Beth Israel Lahey Health

Birmingham, Alabama, United States and 19 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems